Organogenesis's PuraPly®AM Trial Hits Primary Endpoint for Diabetic Foot Ulcers
Summary
Organogenesis announced that its PuraPly®AM product achieved its primary endpoint in a randomized controlled trial for non-healing diabetic foot ulcers, demonstrating statistically significant wound closure at 12 weeks. This positive clinical trial outcome is a significant development, especially following the company's recent warning of a Q1 2026 revenue decline due to adverse CMS reimbursement changes and a clinical trial failure for its ReNu product. The success of PuraPly®AM, a patent-protected product, provides a much-needed positive catalyst and is expected to strongly support its inclusion in future coverage policies, which is crucial for future revenue growth and mitigating recent headwinds. Traders will be watching for the publication of these study results and any updates on securing favorable reimbursement policies.
At the time of this announcement, ORGO was trading at $2.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $288.2M. The 52-week trading range was $2.21 to $7.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.